This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alan Wile, MD

Arch Surg. 1989;124(2):222-224.

Abstract
• Studies of cancer-related immunosuppression reveal the presence of low-molecular-weight (<10 kilodaltons) serum factors capable of in vitro lymphocyte suppression. Removal of suppressor factors by ultrafiltration (UF) prolongs survival in tumor-bearing rabbits. This study determined the prevalence of low-molecular-weight suppressor factors in patients with cancer and normal volunteers and evaluated safety and feasibility of UF in patients with cancer. Intact serum and serum ultrafiltrate from 32 patients with cancer and 24 normal volunteers was examined with mitogen-induced lymphocyte blastogenesis. Eleven (34%) of serum samples from patients with cancer suppressed blastogenesis, while ultrafiltrate was suppressive in 25 (78%). None of the ultrafiltrate from normal volunteers was suppressive. Six patients with cancer underwent UF in a phase I trial, completing 82 sessions. There were no therapy-related complications, and high-performance liquid chromatography showed significant (>90%) posttreatment reduction in serum suppressor factors.

(Arch Surg 1989;124:222-224)

Author Affiliations
From the Division of Surgical Oncology, Department of Surgery, University of California Irvine Medical Center, Orange, Calif.

Footnotes
Accepted for publication Sept 30, 1988.

Read before the Annual Meeting of the Society of Surgical Oncology, New Orleans, May 25, 1988.

Reprint requests to Division of Surgical Oncology, Department of Surgery, University of California Irvine Medical Center, 101 City Dr S, Orange, CA 92668 (Dr Wile).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?